Mesa Laboratories

Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Instruments, Continuous Monitoring, and Biopharmaceutical Development. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Instrument segment designs, manufactures, and markets control instruments and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. The Biopharmaceutical Development segment develops and sells automated systems for protein analysis and peptide synthesis solutions. The Continuous Monitoring segment includes development of systems used to monitor various environmental parameters. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mesa Labs (MLAB) delivered earnings and revenue surprises of 44.96% and 2.55%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Q2 Earnings and Revenues Surpass Estimates

Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Mesa Labs (MLAB) to Report a Decline in Earnings: What to Look Out for

LAKEWOOD, Colo., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that it has completed the previously announced acquisition of Agena Biosciences, Inc. With this highly strategic acquisition, Agena's innovative approach to molecular diagnostics is now paired with Mesa's proven approach to continuous improvement and operational and commercial efficiency. Together, Mesa and Agena will join to pursue the common purpose of Protecting the Vulnerable®.

Mesa Labs Closes Acquisition of Agena Bioscience

Mesa Labs (MLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Mesa Labs (MLAB) Moves 4.5% Higher: Will This Strength Last?

LAKEWOOD, Colo., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “us”, “our”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, announced today that it has entered into a definitive agreement to acquire Agena Bioscience, Inc. (“Agena”) for a cash purchase price of $300 million, subject to customary purchase price adjustments.

Mesa Labs Announces Agreement to Acquire Agena Bioscience, Inc.

Mesa Labs (MLAB) delivered earnings and revenue surprises of -5.88% and 2.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Lags Q1 Earnings Estimates

Shares of Mesa Laboratories (NASDAQ:MLAB) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share increased 53.49% year over year to $1.98, which beat the estimate of $0.25.

Mesa Laboratories: Q4 Earnings Insights

Mesa Labs (MLAB) to Report Q4 Results: Wall Street Expects Earnings Growth

EverBank Financial

Heska

National Western Life Group

CarParts.com, Inc.

Winmark

These seven small-cap stocks have the potential of rebounding and making it big in the post-pandemic reality of 2021. The post 7 Small-Cap Stocks To Buy for Their Big Ambitions appeared first on InvestorPlace.

7 Small-Cap Stocks To Buy for Their Big Ambitions

Mesa Labs (MLAB) delivered earnings and revenue surprises of -0.68% and 5.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Lags Q3 Earnings Estimates

LAKEWOOD, Colo., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the third quarter (“3Q21”) and nine months ended December 31, 2020.

Mesa Labs Reports Third Quarter Results for FY21

Mesa Labs (MLAB) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Mesa Labs (MLAB) delivered earnings and revenue surprises of 78.50% and 5.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Q2 Earnings and Revenues Beat Estimates

LAKEWOOD, Colo., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the second quarter (“2Q21”) and six months ended September 30, 2020.

Mesa Labs Reports Second Quarter Results for FY21

Earnings Preview: Mesa Labs (MLAB) Q2 Earnings Expected to Decline

Mesa Labs (MLAB) delivered earnings and revenue surprises of -6.18% and -5.55%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Misses Q1 Earnings and Revenue Estimates

LAKEWOOD, Colo., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the first quarter (“1Q21”).

Mesa Labs Reports First Quarter Results

Earnings Preview: Mesa Labs (MLAB) Q1 Earnings Expected to Decline

Source:   Mesa Laboratories, Inc. – June 16, 2020 11:30 AM ET

Mesa Laboratories, Inc. Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock in Public Offering

Source: Mesa Laboratories, Inc. - June 9, 2020 8:15 PM ET

Mesa Laboratories, Inc. Announces Upsizing and Pricing of Public Offering of Common Stock

Source: Mesa Laboratories, Inc. – June 8, 2020 4:01 PM ET

Mesa Laboratories, Inc. Announces Proposed Public Offering of Common Stock

Mesa Labs (MLAB) delivered earnings and revenue surprises of -36.45% and -0.85%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Misses Q4 Earnings and Revenue Estimates

Shares of Mesa Laboratories (NASDAQ:MLAB) were unchanged after the company reported Q4 results.

Recap: Mesa Laboratories Q4 Earnings

LAKEWOOD, Colo., May  15, 2020  (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced the election of Shannon Hall to its Board of Directors.  Shannon previously led the Life Sciences business at Bio-Rad Laboratories.

Life Sciences Executive Shannon Hall Joins Mesa Labs Board of Directors

LAKEWOOD, Colo., Jan.  09, 2020  (GLOBE NEWSWIRE) --  Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.  The dividend will be payable on March 16, 2020, to shareholders of record at the close of business on February 28, 2020.

MESA LABS DECLARES  QUARTERLY DIVIDEND

News for Mesa Laboratories Stock (MLAB)